IP Library › Granted Patent US 12,187,795
Granted Patent B2
US 12,187,795 · App. 17/078,602 · Granted Jan 7, 2025

Anti-LAG-3 antibodies and methods of use thereof

Inventors: Nicholas Stuart Wilson (San Carlos, CA); David Adam Savitsky (Boxford, MA); Shawn Michael Jennings (Acton, MA); Marc van Dijk (Bosch en Duin, NL); Cornelia Anne Mundt (Lörrach, DE)
Assignee: AGENUS INC.
C07K16/2803A61K47/6873A61P35/00C07K2317/20C07K2317/24C07K2317/34C07K2317/55C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,187,795
App. No.
17/078,602
Granted
Jan 7, 2025
Kind
B2
Abstract

The instant disclosure provides antibodies that specifically bind to LAG-3 (e.g., human LAG-3) and antagonize LAG-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Claims (29)

1. An isolated polynucleotide encoding an antibody comprising complementarity determining regions CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3,

wherein CDRH1, CDRH2, and CDRH3 are found in a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 65; and CDRL1, CDRL2 and CDRL3 are found in a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 73.

2. The isolated polynucleotide of claim 1 , wherein CDRH1, CDRH2 and CDRH3 comprise the amino acid sequences set forth in SEQ ID NOs: 79, 90, and 98 and/or CDRL1, CDRL2 and CDRL3 comprise the amino acid sequences set forth in SEQ ID NOs: 100, 104, and 105.

3. The isolated polynucleotide of claim 1 , wherein CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 comprise the amino acid sequences set forth in SEQ ID NOs: 79, 90, 98, 100, 104, and 105, respectively.

4. The isolated polynucleotide of claim 1 , wherein the VH comprises the amino acid sequence of SEQ ID NO: 65.

5. The isolated polynucleotide of claim 1 , wherein the VL comprises the amino acid sequence of SEQ ID NO: 73.

6. The isolated polynucleotide of claim 1 , wherein the VH comprises the amino acid sequence of SEQ ID NO: 65; and the VL comprises the amino acid sequence of SEQ ID NO: 73.

7. The isolated polynucleotide of claim 1 , wherein the antibody comprises:

(a) a heavy chain variable framework region that is or is derived from an amino acid sequence encoded by a human gene, optionally wherein said amino acid sequence is selected from the group consisting of IGHV1-46*01 (SEQ ID NO: 153), IGHV1-69-2*01 (SEQ ID NO: 154), IGHV1-3*01 (SEQ ID NO: 155), IGHV1-24*01 (SEQ ID NO: 156), IGHV1-2*01 (SEQ ID NO: 157), IGHV1-45*01 (SEQ ID NO: 158), and IGHV1-18*01 (SEQ ID NO: 159); and/or

(b) a light chain variable framework region that is or is derived from an amino acid sequence encoded by a human gene, optionally wherein said amino acid sequence is selected from the group consisting of IGKV3-20*01 (SEQ ID NO: 160), IGKV3D-15*01 (SEQ ID NO: 161), IGKV3-15*01 (SEQ ID NO: 161), IGKV3D-20*01 (SEQ ID NO: 162), IGKV3D-7*01 (SEQ ID NO: 163), IGKV1-9*01 (SEQ ID NO: 164), and IGKV3-11*01 (SEQ ID NO: 165).

8. The isolated polynucleotide of claim 7 , wherein the antibody comprises:

(a) a heavy chain variable framework region that is derived from the amino acid sequence IGHV1-46*01 (SEQ ID NO: 153), wherein at least one amino acid in the amino acid sequence IGHV1-46*01 (SEQ ID NO: 153) is substituted with an amino acid in an analogous position in a corresponding non-human heavy chain variable framework region, optionally wherein the amino acid substitution is at an amino acid position selected from the group consisting of 4, 5, 12, 23, 27, 28, 29, 30, 48, 69, 71, 75, 76, 80, 81, and 94, further optionally wherein the amino acid substitution is selected from the group consisting of 4M, 5K, 12V, 23T, 27F, 28N, 29I, 30K, 481, 691, 71A, 75S, 76N, 80L, 81Q, and 94T; and/or

(b) a light chain variable framework region that is derived from the amino acid sequence IGKV3-20*01 (SEQ ID NO: 160), wherein at least one amino acid in the amino acid sequence IGKV3-20*01 (SEQ ID NO: 160) is substituted with an amino acid in an analogous position in a corresponding non-human light chain variable framework region, optionally wherein the amino acid substitution is at an amino acid position selected from the group consisting of 3, 22, 36, 43, 47, 58, 70, and 71, further optionally wherein the amino acid substitution is selected from the group consisting of 3L, 22T, 36F, 43S, 47W, 58V, 70S, and 71Y,

wherein the position of the amino acid substitution is indicated according to the Kabat numbering system.

9. The isolated polynucleotide of claim 1 , wherein the antibody comprises a heavy chain constant region selected from the group consisting of human IgG 1 , IgG 2 , IgG 3 , IgG 4 , IgA 1 , and IgA 2 , and optionally wherein the heavy chain constant region is:

(a) an IgG 1 heavy chain constant region comprising a N297A mutation, optionally wherein the heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 194;

(b) an IgG 1 heavy chain constant region comprising a N297Q mutation;

(c) a non-fucosylated IgG 1 heavy chain constant region; and/or

(d) an IgG 4 heavy chain constant region comprises a S228P mutation, optionally wherein the heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 196,

wherein the amino acid residues are numbered according to the EU numbering system.

10. The isolated polynucleotide of claim 1 , wherein the antibody comprises a light chain constant region selected from the group consisting of human IgG κ and IgGλ, and optionally wherein the light chain constant region is an IgG κ light chain constant region comprising the amino acid sequence of SEQ ID NO: 198 or 219.

11. The isolated polynucleotide of claim 1 , wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 169.

12. The isolated polynucleotide of claim 1 , wherein the antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 187.

13. The isolated polynucleotide of claim 1 , wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 169 and a light chain comprising the amino acid sequence of SEQ ID NO: 187.

14. A vector comprising the polynucleotide of claim 1 .

15. A recombinant host cell comprising the polynucleotide of claim 1 .

16. A recombinant host cell comprising an isolated polynucleotide encoding the VH of claim 1 , and an isolated polynucleotide encoding the VL of claim 1 ; or an isolated polynucleotide encoding the heavy chain of the antibody of claim 11 , and an isolated polynucleotide encoding the light chain of the antibody of claim 12 .

17. A method of producing an antibody that binds to human LAG-3, the method comprising culturing the host cell of claim 15 so that the polynucleotide is expressed and the antibody is produced.

18. A method of producing an antibody that binds to human LAG-3, the method comprising culturing the host cell of claim 16 so that the polynucleotide is expressed and the antibody is produced.

Assignments (4)
SECURITY INTEREST Recorded Mar 31, 2025
From: AGENUS, INC.
To: LIGAND PHARMACEUTICALS INCORPORATED
Reel/Frame 070680/0634 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 1, 2021
From: MUNDT, CORNELIA ANNE; VAN DIJK, MARC
To: AGENUS SWITZERLAND INC.
Reel/Frame 056399/0091 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 1, 2021
From: WILSON, NICHOLAS STUART; SAVITSKY, DAVID ADAM; JENNINGS, SHAWN MICHAEL
To: AGENUS INC.
Reel/Frame 056399/0143 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 1, 2021
From: AGENUS SWITZERLAND INC.
To: AGENUS INC.
Reel/Frame 056399/0187 →
Continuity (4)
Division 15730249 · Oct 11, 2017
Provisional Application 62420280 · Nov 10, 2016
Provisional Application 62406766 · Oct 11, 2016
Related Publication 20210054074A1 · Feb 25, 2021
References Cited (400)
US 5225539A · Winter · 1993 [cited by applicant]
US 5403484A · Ladner et al. · 1995 [cited by applicant]
US 5413923A · Kucherlapati et al. · 1995 [cited by applicant]
US 5427908A · Dower et al. · 1995 [cited by applicant]
US 5516637A · Huang et al. · 1996 [cited by applicant]
US 5530101A · Queen et al. · 1996 [cited by applicant]
US 5545806A · Lonberg et al. · 1996 [cited by applicant]
US 5565332A · Hoogenboom et al. · 1996 [cited by applicant]
US 5569825A · Lonberg et al. · 1996 [cited by applicant]
US 5571698A · Ladner et al. · 1996 [cited by applicant]
US 5580717A · Dower et al. · 1996 [cited by applicant]
US 5585089A · Queen et al. · 1996 [cited by applicant]
US 5585097A · Bolt et al. · 1996 [cited by applicant]
US 5624821A · Winter et al. · 1997 [cited by applicant]
US 5625126A · Lonberg et al. · 1997 [cited by applicant]
US 5633425A · Lonberg et al. · 1997 [cited by applicant]
US 5648260A · Winter et al. · 1997 [cited by applicant]
US 5658727A · Barbas et al. · 1997 [cited by applicant]
US 5661016A · Lonberg et al. · 1997 [cited by applicant]
US 5677425A · Bodmer et al. · 1997 [cited by applicant]
US 5698426A · Huse · 1997 [cited by applicant]
US 5709874A · Hanson et al. · 1998 [cited by applicant]
US 5733743A · Johnson et al. · 1998 [cited by applicant]
US 5750753A · Kimae et al. · 1998 [cited by applicant]
US 5759542A · Gurewich · 1998 [cited by applicant]
US 5766886A · Studnicka et al. · 1998 [cited by applicant]
US 5780225A · Wigler et al. · 1998 [cited by applicant]
US 5807715A · Morrison et al. · 1998 [cited by applicant]
US 5814318A · Lonberg et al. · 1998 [cited by applicant]
US 5821047A · Garrard et al. · 1998 [cited by applicant]
US 5837242A · Holliger et al. · 1998 [cited by applicant]
US 5840674A · Yatvin et al. · 1998 [cited by applicant]
US 5860957A · Jacobsen et al. · 1999 [cited by applicant]
US 5869046A · Presta et al. · 1999 [cited by applicant]
US 5869620A · Whitlow et al. · 1999 [cited by applicant]
US 5885793A · Griffiths et al. · 1999 [cited by applicant]
US 5900252A · Calanchi et al. · 1999 [cited by applicant]
US 5939598A · Kucherlapati et al. · 1999 [cited by applicant]
US 5948433A · Burton et al. · 1999 [cited by applicant]
US 5965726A · Pavlakis et al. · 1999 [cited by applicant]
US 5969108A · McCafferty et al. · 1999 [cited by applicant]
US 5972366A · Haynes et al. · 1999 [cited by applicant]
US 5983134A · Ostrow · 1999 [cited by applicant]
US 5985307A · Hanson et al. · 1999 [cited by applicant]
US 5985317A · Venkateshwaran et al. · 1999 [cited by applicant]
US 5989830A · Davis et al. · 1999 [cited by applicant]
US 6004534A · Langer et al. · 1999 [cited by applicant]
US 6005079A · Casterman et al. · 1999 [cited by applicant]
US 6010715A · Wick et al. · 2000 [cited by applicant]
US 6024975A · D'Angelo et al. · 2000 [cited by applicant]
US 6039975A · Shah et al. · 2000 [cited by applicant]
US 6048736A · Kosak · 2000 [cited by applicant]
US 6060082A · Chen et al. · 2000 [cited by applicant]
US 6071495A · Unger et al. · 2000 [cited by applicant]
US 6075181A · Kucherlapati et al. · 2000 [cited by applicant]
US 6120751A · Unger · 2000 [cited by applicant]
US 6121022A · Presta et al. · 2000 [cited by applicant]
US 6131570A · Schuster et al. · 2000 [cited by applicant]
US 6132992A · Ledbetter et al. · 2000 [cited by applicant]
US 6139865A · Friend et al. · 2000 [cited by applicant]
US 6143273A · Faure et al. · 2000 [cited by applicant]
US 6150184A · Evans et al. · 2000 [cited by applicant]
US 6165745A · Ward et al. · 2000 [cited by applicant]
US 6167301A · Flower et al. · 2000 [cited by applicant]
US 6174666B1 · Pavlakis et al. · 2001 [cited by applicant]
US 6194551B1 · Idusogie et al. · 2001 [cited by applicant]
US 6197524B1 · Romagnani · 2001 [cited by applicant]
US 6253872B1 · Neumann · 2001 [cited by applicant]
US 6256533B1 · Yuzhakov et al. · 2001 [cited by applicant]
US 6261595B1 · Stanley et al. · 2001 [cited by applicant]
US 6267983B1 · Fujii et al. · 2001 [cited by applicant]
US 6271359B1 · Norris et al. · 2001 [cited by applicant]
US 6274552B1 · Tamarkin et al. · 2001 [cited by applicant]
US 6277375B1 · Ward · 2001 [cited by applicant]
US 6291664B1 · Pavlakis et al. · 2001 [cited by applicant]
US 6316652B1 · Steliou · 2001 [cited by applicant]
US 6331415B1 · Cabilly et al. · 2001 [cited by applicant]
US 6383492B1 · Srivastava et al. · 2002 [cited by applicant]
US 6391306B1 · Srivastava et al. · 2002 [cited by applicant]
US 6403095B1 · Srivastava et al. · 2002 [cited by applicant]
US 6407213B1 · Carter et al. · 2002 [cited by applicant]
US 6410026B1 · Srivastava · 2002 [cited by applicant]
US 6414132B1 · Pavlakis et al. · 2002 [cited by applicant]
US 6436404B1 · Srivastava et al. · 2002 [cited by applicant]
US 6447780B1 · Srivastava et al. · 2002 [cited by applicant]
US 6447781B1 · Srivastava · 2002 [cited by applicant]
US 6610659B1 · Pramod · 2003 [cited by applicant]
US 6645495B1 · Kensil et al. · 2003 [cited by applicant]
US 6737056B1 · Presta · 2004 [cited by applicant]
US 6794498B2 · Pavlakis et al. · 2004 [cited by applicant]
US 6808710B1 · Wood et al. · 2004 [cited by applicant]
US 6984720B1 · Korman et al. · 2006 [cited by applicant]
US 7029678B2 · Momin et al. · 2006 [cited by applicant]
US 7034121B2 · Carreno et al. · 2006 [cited by applicant]
US 7183076B2 · Arathoon et al. · 2007 [cited by applicant]
US 7332582B2 · Hardy et al. · 2008 [cited by applicant]
US 7411057B2 · Hanson et al. · 2008 [cited by applicant]
US 7488802B2 · Collins et al. · 2009 [cited by applicant]
US 7658921B2 · Dall'Acqua et al. · 2010 [cited by applicant]
US 7709226B2 · Foote · 2010 [cited by applicant]
US 7858589B2 · Kensil · 2010 [cited by applicant]
US 7943743B2 · Korman et al. · 2011 [cited by applicant]
US 7951917B1 · Arathoon et al. · 2011 [cited by applicant]
US 7972993B2 · Slootstra et al. · 2011 [cited by applicant]
US 8088449B2 · Bailey et al. · 2012 [cited by applicant]
US 8114845B2 · Langermann et al. · 2012 [cited by applicant]
US 8168179B2 · Honjo et al. · 2012 [cited by applicant]
US 8168757B2 · Finnefrock et al. · 2012 [cited by applicant]
US 8217149B2 · Irving et al. · 2012 [cited by applicant]
US 8227577B2 · Klein et al. · 2012 [cited by applicant]
US 8354509B2 · Carven et al. · 2013 [cited by applicant]
US 8354847B2 · Robinson · 2013 [cited by applicant]
US 8551481B2 · Pardoll et al. · 2013 [cited by applicant]
US 8552154B2 · Freeman et al. · 2013 [cited by applicant]
US 8586713B2 · Davis et al. · 2013 [cited by applicant]
US 8591886B2 · Ponath et al. · 2013 [cited by applicant]
US 8686119B2 · Rotem-Yehudar et al. · 2014 [cited by applicant]
US 8697845B2 · Ward et al. · 2014 [cited by applicant]
US 8735553B1 · Li et al. · 2014 [cited by applicant]
US 8747847B2 · Rotem-Yehudar et al. · 2014 [cited by applicant]
US 8779105B2 · Korman et al. · 2014 [cited by applicant]
US 8779108B2 · Queva et al. · 2014 [cited by applicant]
US 8927697B2 · Davis et al. · 2015 [cited by applicant]
US 8981063B2 · Chen · 2015 [cited by applicant]
US 8993731B2 · Tyson · 2015 [cited by applicant]
US 9005629B2 · Pardoll et al. · 2015 [cited by applicant]
US 9074000B2 · Scheinberg et al. · 2015 [cited by applicant]
US 9102727B2 · Freeman et al. · 2015 [cited by applicant]
US 9132281B2 · Zeng et al. · 2015 [cited by applicant]
US 9175082B2 · Zhou et al. · 2015 [cited by applicant]
US 9205148B2 · Langermann et al. · 2015 [cited by applicant]
US 9244059B2 · Triebel et al. · 2016 [cited by applicant]
US 9425591B2 · Sharma et al. · 2016 [cited by applicant]
US 9505839B2 · Lonberg et al. · 2016 [cited by applicant]
US 9515982B2 · Belghoul · 2016 [cited by applicant]
US 9850306B2 · Bedi et al. · 2017 [cited by applicant]
US 9902772B2 · Zhou et al. · 2018 [cited by applicant]
US 9908936B2 · Triebel et al. · 2018 [cited by applicant]
US 10081681B2 · Alan et al. · 2018 [cited by applicant]
US 10144778B2 · Eisenbach-Schwartz et al. · 2018 [cited by applicant]
US 10160806B2 · Ezio et al. · 2018 [cited by applicant]
US 10188730B2 · Linda et al. · 2019 [cited by applicant]
US 10844119B2 · Wilson et al. · 2020 [cited by applicant]
US 10882908B2 · Wilson et al. · 2021 [cited by applicant]
US 20030232323A1 · Freeman et al. · 2003 [cited by applicant]
US 20040014194A1 · Beyer et al. · 2004 [cited by applicant]
US 20050042664A1 · Wu et al. · 2005 [cited by applicant]
US 20050048549A1 · Cao et al. · 2005 [cited by applicant]
US 20070099240A1 · Puijk et al. · 2007 [cited by applicant]
US 20080139407A1 · Slootstra et al. · 2008 [cited by applicant]
US 20090123477A1 · Hanke et al. · 2009 [cited by applicant]
US 20090304679A1 · Weidanz · 2009 [cited by applicant]
US 20100203056A1 · Irving et al. · 2010 [cited by applicant]
US 20110150892A1 · Thudium et al. · 2011 [cited by applicant]
US 20130202623A1 · Chomont et al. · 2013 [cited by applicant]
US 20130267688A1 · Chin et al. · 2013 [cited by applicant]
US 20130291136A1 · Freeman et al. · 2013 [cited by applicant]
US 20130323249A1 · Zhou et al. · 2013 [cited by applicant]
US 20140044738A1 · Langermann et al. · 2014 [cited by applicant]
US 20140093511A1 · Lonberg et al. · 2014 [cited by applicant]
US 20140105914A1 · Jones et al. · 2014 [cited by applicant]
US 20140134191A1 · Weidanz et al. · 2014 [cited by applicant]
US 20140286935A1 · Hamblin et al. · 2014 [cited by applicant]
US 20140341917A1 · Nastri et al. · 2014 [cited by applicant]
US 20140356363A1 · Zhou et al. · 2014 [cited by applicant]
US 20150174268A1 · Li et al. · 2015 [cited by applicant]
US 20150202291A1 · Bosch et al. · 2015 [cited by applicant]
US 20150203580A1 · Papadopoulos et al. · 2015 [cited by applicant]
US 20150225483A1 · Lo · 2015 [cited by applicant]
US 20150322119A1 · Engelhardt et al. · 2015 [cited by applicant]
US 20150346208A1 · Couto et al. · 2015 [cited by applicant]
US 20150355184A1 · Pierce et al. · 2015 [cited by applicant]
US 20160075783A1 · King et al. · 2016 [cited by applicant]
US 20160145355A1 · Saha et al. · 2016 [cited by applicant]
US 20160159905A1 · Abdiche et al. · 2016 [cited by applicant]
US 20160185870A1 · Van Eenennaam et al. · 2016 [cited by applicant]
US 20160193239A1 · Baylin et al. · 2016 [cited by applicant]
US 20160222121A1 · Johnson et al. · 2016 [cited by applicant]
US 20160355589A1 · Williams et al. · 2016 [cited by applicant]
US 20160376365A1 · Gurney et al. · 2016 [cited by applicant]
US 20170007698A1 · Kim et al. · 2017 [cited by applicant]
US 20170056391A1 · Li · 2017 [cited by applicant]
US 20170101472A1 · Ullman et al. · 2017 [cited by applicant]
US 20170106048A1 · Kunz et al. · 2017 [cited by applicant]
US 20170137517A1 · Bowman et al. · 2017 [cited by applicant]
US 20170143780A1 · Zitvogel et al. · 2017 [cited by applicant]
US 20170145099A1 · Ito et al. · 2017 [cited by applicant]
US 20170165230A1 · Rudd et al. · 2017 [cited by applicant]
US 20170184604A1 · Lee et al. · 2017 [cited by applicant]
US 20170209574A1 · Cao et al. · 2017 [cited by applicant]
US 20170216403A1 · Wittrup et al. · 2017 [cited by applicant]
US 20170239338A1 · Szalay et al. · 2017 [cited by applicant]
US 20170247459A1 · Cannarile et al. · 2017 [cited by applicant]
US 20170275353A1 · Sheng et al. · 2017 [cited by applicant]
US 20170281569A1 · Udono et al. · 2017 [cited by applicant]
US 20170281764A1 · Tso et al. · 2017 [cited by applicant]
US 20170296659A1 · Lebwohl et al. · 2017 [cited by applicant]
US 20170313775A1 · Diaz et al. · 2017 [cited by applicant]
US 20170320950A1 · Snyder et al. · 2017 [cited by applicant]
US 20170334995A1 · Zettl et al. · 2017 [cited by applicant]
US 20170335281A1 · Loew et al. · 2017 [cited by applicant]
US 20170340733A1 · Cao · 2017 [cited by applicant]
US 20170355774A1 · Delfino et al. · 2017 [cited by applicant]
US 20170360932A1 · Parry · 2017 [cited by applicant]
US 20180015161A1 · Weiner et al. · 2018 [cited by applicant]
US 20180021378A1 · Kang et al. · 2018 [cited by applicant]
US 20180021407A1 · Gurney · 2018 [cited by applicant]
US 20180028626A1 · Slos et al. · 2018 [cited by applicant]
US 20180066053A1 · Keler et al. · 2018 [cited by applicant]
US 20180186878A1 · Rosenthal · 2018 [cited by applicant]
US 20180207212A1 · Conner · 2018 [cited by applicant]
US 20180214583A1 · Scholz · 2018 [cited by applicant]
US 20180221508A1 · Kadiyala et al. · 2018 [cited by applicant]
US 20180230431A1 · Bi et al. · 2018 [cited by applicant]
US 20180244773A1 · Gutierrez et al. · 2018 [cited by applicant]
US 20180250352A1 · Conner · 2018 [cited by applicant]
US 20180318365A1 · Yeung et al. · 2018 [cited by applicant]
US 20180326058A1 · Tsunenari et al. · 2018 [cited by applicant]
US 20180340025A1 · Dranoff et al. · 2018 [cited by applicant]
US 20180353524A1 · Gardai et al. · 2018 [cited by applicant]
US 20180355039A1 · Freeman et al. · 2018 [cited by applicant]
US 20180369375A1 · De Waal Malefyt et al. · 2018 [cited by applicant]
US 20180371083A1 · Williams et al. · 2018 [cited by applicant]
US 20190010231A1 · Rothe et al. · 2019 [cited by applicant]
US 20190015507A1 · Xu et al. · 2019 [cited by applicant]
US 20190016800A1 · Kang et al. · 2019 [cited by applicant]
US 20190023804A1 · Onik et al. · 2019 [cited by applicant]
US 20190031757A1 · Levade et al. · 2019 [cited by applicant]
US 20190038671A1 · Fan et al. · 2019 [cited by applicant]
US 20190038763A1 · Levade et al. · 2019 [cited by applicant]
US 20190040136A1 · Wang et al. · 2019 [cited by applicant]
EP 0239400A2 · 1987 [cited by applicant]
EP 0519596A1 · 1992 [cited by applicant]
EP 0592106A1 · 1994 [cited by applicant]
EP 1897548A1 · 2008 [cited by applicant]
EP 3010340A2 · 2016 [cited by applicant]
EP 3192805A1 · 2017 [cited by applicant]
EP 3226900A1 · 2017 [cited by applicant]
WO WO1986005807A1 · 1986 [cited by applicant]
WO WO1989001036A1 · 1989 [cited by applicant]
WO WO1990002809A1 · 1990 [cited by applicant]
WO WO1991009967A1 · 1991 [cited by applicant]
WO WO1991010737A1 · 1991 [cited by applicant]
WO WO1991010741A1 · 1991 [cited by applicant]
WO WO1992001047A1 · 1992 [cited by applicant]
WO WO1992018619A1 · 1992 [cited by applicant]
WO WO1992022324A1 · 1992 [cited by applicant]
WO WO1993011236A1 · 1993 [cited by applicant]
WO WO1993017105A1 · 1993 [cited by applicant]
WO WO1994004678A1 · 1994 [cited by applicant]
WO WO1994025591A1 · 1994 [cited by applicant]
WO WO1994029351A2 · 1994 [cited by applicant]
WO WO1995015982A2 · 1995 [cited by applicant]
WO WO1995020401A1 · 1995 [cited by applicant]
WO WO1996033735A1 · 1996 [cited by applicant]
WO WO1996034096A1 · 1996 [cited by applicant]
WO WO1997003695A1 · 1997 [cited by applicant]
WO WO1997013844A1 · 1997 [cited by applicant]
WO WO1997034631A1 · 1997 [cited by applicant]
WO WO1998016654A1 · 1998 [cited by applicant]
WO WO1998023289A1 · 1998 [cited by applicant]
WO WO1998024893A2 · 1998 [cited by applicant]
WO WO1998046645A2 · 1998 [cited by applicant]
WO WO1998050433A2 · 1998 [cited by applicant]
WO WO2000042072A2 · 2000 [cited by applicant]
WO WO2001044301A1 · 2001 [cited by applicant]
WO WO2002060919A2 · 2002 [cited by applicant]
WO WO2008132601A1 · 2008 [cited by applicant]
WO WO2010005958A2 · 2010 [cited by applicant]
WO WO2010019570A2 · 2010 [cited by applicant]
WO 2010059654A1 · 2010 [cited by applicant]
WO WO2013033091A1 · 2013 [cited by applicant]
WO WO2014022758A1 · 2014 [cited by applicant]
WO WO2014055897A2 · 2014 [cited by applicant]
WO WO2014100079A1 · 2014 [cited by applicant]
WO WO2014108483A1 · 2014 [cited by applicant]
WO WO2014179664A2 · 2014 [cited by applicant]
WO WO2014206107A1 · 2014 [cited by applicant]
WO WO2014207064A1 · 2014 [cited by applicant]
WO WO2014209804A1 · 2014 [cited by applicant]
WO WO2015019284A2 · 2015 [cited by applicant]
WO WO2015036394A1 · 2015 [cited by applicant]
WO WO2015058573A1 · 2015 [cited by applicant]
WO WO2015061668A1 · 2015 [cited by applicant]
WO WO2015061752A1 · 2015 [cited by applicant]
WO WO2015085847A1 · 2015 [cited by applicant]
WO WO2015109124A2 · 2015 [cited by applicant]
WO WO2015125652A1 · 2015 [cited by applicant]
WO WO2015131176A1 · 2015 [cited by applicant]
WO WO2015174439A1 · 2015 [cited by applicant]
WO WO2015195163A1 · 2015 [cited by applicant]
WO WO2015200119A1 · 2015 [cited by applicant]
WO WO2016000619A1 · 2016 [cited by applicant]
WO WO2016015675A1 · 2016 [cited by applicant]
WO WO2016015685A1 · 2016 [cited by applicant]
WO WO2016020538A1 · 2016 [cited by applicant]
WO WO2016020856A2 · 2016 [cited by applicant]
WO WO2016028672A1 · 2016 [cited by applicant]
WO WO2016030350A1 · 2016 [cited by applicant]
WO WO2016057898A1 · 2016 [cited by applicant]
WO WO2016073770A1 · 2016 [cited by applicant]
WO WO2016081746A2 · 2016 [cited by applicant]
WO WO2016106302A1 · 2016 [cited by applicant]
WO WO2016126858A2 · 2016 [cited by applicant]
WO WO2016168361A1 · 2016 [cited by applicant]
WO WO2016180781A1 · 2016 [cited by applicant]
WO WO2016193680A1 · 2016 [cited by applicant]
WO WO2016197204A1 · 2016 [cited by applicant]
WO WO2016200782A1 · 2016 [cited by applicant]
WO WO2017037203A1 · 2017 [cited by applicant]
WO WO2017053748A2 · 2017 [cited by applicant]
WO WO2017059095A1 · 2017 [cited by applicant]
WO WO2017068186A1 · 2017 [cited by applicant]
WO WO2017087547A1 · 2017 [cited by applicant]
WO WO2017087901A2 · 2017 [cited by applicant]
WO WO2017091611A1 · 2017 [cited by applicant]
WO WO2017106278A1 · 2017 [cited by applicant]
WO WO2017149150A1 · 2017 [cited by applicant]
WO WO2017152085A1 · 2017 [cited by applicant]
WO WO2017156349A1 · 2017 [cited by applicant]
WO WO2017157964A1 · 2017 [cited by applicant]
WO WO2017160717A2 · 2017 [cited by applicant]
WO WO2017165732A1 · 2017 [cited by applicant]
WO WO2017174331A1 · 2017 [cited by applicant]
WO WO2017181139A2 · 2017 [cited by applicant]
WO WO2017193094A1 · 2017 [cited by applicant]
WO WO2017193098A1 · 2017 [cited by applicant]
WO WO2017201502A1 · 2017 [cited by applicant]
WO WO2017205014A1 · 2017 [cited by applicant]
WO WO2017207628A1 · 2017 [cited by applicant]
WO WO2017219995A1 · 2017 [cited by applicant]
WO WO2017220555A1 · 2017 [cited by applicant]
WO WO2017223422A1 · 2017 [cited by applicant]
WO WO2018013534A1 · 2018 [cited by applicant]
WO WO2018045110A1 · 2018 [cited by applicant]
WO WO2018053242A1 · 2018 [cited by applicant]
WO WO2018058111A1 · 2018 [cited by applicant]
WO WO2018069500A2 · 2018 [cited by applicant]
WO WO2018071500A1 · 2018 [cited by applicant]
WO WO2018129553A1 · 2018 [cited by applicant]
WO WO2018129559A1 · 2018 [cited by applicant]
WO WO2018137598A1 · 2018 [cited by applicant]
WO WO2018148378A1 · 2018 [cited by applicant]
WO WO2018152687A1 · 2018 [cited by applicant]
WO WO2018156494A1 · 2018 [cited by applicant]
WO WO2018160671A1 · 2018 [cited by applicant]
WO WO2018160754A2 · 2018 [cited by applicant]
WO WO2018167320A1 · 2018 [cited by applicant]
WO WO2018185046A1 · 2018 [cited by applicant]
WO WO2018185135A1 · 2018 [cited by applicant]
WO WO2018185232A1 · 2018 [cited by applicant]
WO WO2018186924A1 · 2018 [cited by applicant]
WO WO2018195552A1 · 2018 [cited by applicant]
WO WO2018204374A1 · 2018 [cited by applicant]
WO WO2018204760A1 · 2018 [cited by applicant]
WO WO2018208868A1 · 2018 [cited by applicant]
WO WO2018218056A1 · 2018 [cited by applicant]
WO WO2018219956A1 · 2018 [cited by applicant]
WO WO2018222711A2 · 2018 [cited by applicant]
WO WO2018222718A1 · 2018 [cited by applicant]
WO WO2018222722A2 · 2018 [cited by applicant]
WO WO2018223002A1 · 2018 [cited by applicant]
WO WO2018223004A1 · 2018 [cited by applicant]
WO WO2018223182A1 · 2018 [cited by applicant]
WO WO2018226336A1 · 2018 [cited by applicant]
WO WO2018226985A2 · 2018 [cited by applicant]
WO WO2018232195A1 · 2018 [cited by applicant]
WO WO2018234367A1 · 2018 [cited by applicant]
WO WO2018237173A1 · 2018 [cited by applicant]
WO WO2018237326A1 · 2018 [cited by applicant]
WO WO2019003164A1 · 2019 [cited by applicant]
WO WO2019008386A1 · 2019 [cited by applicant]
WO WO2019009728A1 · 2019 [cited by applicant]
WO WO2019014665A1 · 2019 [cited by applicant]
WO WO2019018730A1 · 2019 [cited by applicant]
WO WO2019020593A1 · 2019 [cited by applicant]
WO WO2019023525A1 · 2019 [cited by applicant]
Rudikoff et al. “Single amino acid substitution altering antigen-binding specificity.” Proc. Natl. Acad. Sci. USA. 1982;79:6:1979-1983. [cited by applicant]
Ferrara et al., “Recombinant renewable polyclonal antibodies,” MAbs. 2015;7(1):32-41. [cited by applicant]
Lloyd et al., “Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens,” Protein Eng Des Sel. Mar. 2009;22(3):159-68. [cited by applicant]
Edwards et al., “The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS,” J Mol Biol. Nov. 14, 2003;334(1):103-18. [cited by applicant]
Agenus, “Agenus IR Deck,” Jan. 2017. [cited by applicant]
Anderson et al., “Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation,” Immunity. May 17, 2016;44(5):989-1004. [cited by applicant]
Baixeras et al., “Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens,” J Exp Med. 1992;176(2):327-37. [cited by applicant]
Berman et al., “The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: the Bristol-Myers Squibb experience,” Pharmacol Ther. Apr. 2015;148:132-53. [cited by applicant]
Blackburn et al., “Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection,” Nat Immunol. Jan. 2009;10(1):29-37. [cited by applicant]
Brignone et al., “First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3lg) enhances immune responses and antitumor activity,” J Transl Med. Jul. 23, 2010;8:71. [cited by applicant]
Brignone et al., “A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma,” Clin Cancer Res. Oct. 1, 2009;15(19):6225-31. [cited by applicant]
Butler et al., “Therapeutic PD-L1 and LAG-3 blockade rapidly clears established blood-stage Plasmodium infection,” Nat Immunol. Feb. 2012;13(2):188-95. [cited by applicant]
Caldas et al., “Design and synthesis of germline-based hemi-humanized single-chain Fv against the CD18 surface antigen,” Protein Eng. May 2000;13(5):353-60. [cited by applicant]
Camisaschi et al., “LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites,” J Immunol. Jun. 1, 2010;184(11):6545-51. [cited by applicant]
Champe et al., “Monoclonal antibodies that block the activity of leukocyte function-associated antigen 1 recognize three discrete epitopes in the inserted domain of CD11a,” J Biol Chem. Jan. 20, 1995;270(3):1388-94. [cited by applicant]
Dall'Acqua et al., “Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn),” J Biol Chem. Aug. 18, 2006;281(33):23514-24. [cited by applicant]
Demeure et al., “T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts,” Eur J Cancer. Sep. 2… [cited by applicant]
Di Domizio et al., “Plasmacytoid dendritic cells in melanoma: can we revert bad into good?” J Invest Dermatol. Jul. 2014;134(7):1797-1800. [cited by applicant]
Drake, “Combined Immune Checkpoint Blockade,” Semin Oncol. Aug. 2015;42(4):656-62. [cited by applicant]
Fehlings et al., “Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells,” Nat Commun. Sep. 15, 2017;8(1):562. [cited by applicant]
Freeman and Sharpe, “A new therapeutic strategy for malaria: targeting T cell exhaustion,” Nat Immunol. Jan. 19, 2012;13(2):113-5. [cited by applicant]
Gagliani et al., “Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells,” Nat Med. Jun. 2013;19(6):739-46. [cited by applicant]
Gandhi et al., “Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients,” Blood. Oct. 1, 2006;108(7)… [cited by applicant]